VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

[1]  T. Shanafelt,et al.  VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. , 2004, Blood.

[2]  S. Dias,et al.  Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. , 2004, Blood.

[3]  J. Darnell,et al.  Essential Role of STAT3 in Postnatal Survival and Growth Revealed by Mice Lacking STAT3 Serine 727 Phosphorylation , 2004, Molecular and Cellular Biology.

[4]  L. Claesson‐Welsh,et al.  VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.

[5]  J. Karras,et al.  macrophage survival Serine phosphorylation of STAT 3 is essential for Mcl-1 expression and , 2003 .

[6]  M. L. Le Beau,et al.  A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. , 2003, Blood.

[7]  Yuhai Tu,et al.  Identification of a global gene expression signature of B-chronic lymphocytic leukemia. , 2003, Molecular cancer research : MCR.

[8]  B. Frei,et al.  Tea Catechins and Polyphenols: Health Effects, Metabolism, and Antioxidant Functions , 2003, Critical reviews in food science and nutrition.

[9]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[10]  J. Turkson,et al.  Cytoplasmic transport of Stat3 by receptor‐mediated endocytosis , 2002, The EMBO journal.

[11]  N. Kay,et al.  B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules , 2002, Leukemia.

[12]  M. Bartoli,et al.  Vascular Endothelial Growth Factor Activates STAT Proteins in Aortic Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[13]  Thomas S. Lin,et al.  STAT signaling in the pathogenesis and treatment of leukemias , 2000, Oncogene.

[14]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[15]  R. Jove,et al.  Activation of Stat3 preassembled with platelet-derived growth factor β receptors requires Src kinase activity , 2000, Oncogene.

[16]  P. Cohen,et al.  Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Williams,et al.  p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons , 1999, The EMBO journal.

[18]  M. Keating.  Chronic lymphocytic leukemia. , 1999, Seminars in oncology.

[19]  J. Johnston,et al.  Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. , 1999, Journal of immunology.

[20]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[21]  J. Ritz,et al.  Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling , 1999, Nature Medicine.

[22]  H. Hutchings,et al.  Signal relays in the VEGF system. , 1999, Frontiers in bioscience : a journal and virtual library.

[23]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[25]  T. Decker,et al.  Stat1 combines signals derived from IFN‐γ and LPS receptors during macrophage activation , 1998, The EMBO journal.

[26]  John Calvin Reed.  Molecular biology of chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[27]  Yihai Cao,et al.  Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.

[28]  J. Ritz,et al.  B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. , 1997, The Journal of clinical investigation.

[29]  Jacques Landry,et al.  p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells , 1997, Oncogene.

[30]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[31]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[32]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[33]  Janet Rossant,et al.  A Requirement for Flk1 in Primitive and Definitive Hematopoiesis and Vasculogenesis , 1997, Cell.

[34]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[35]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[36]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[37]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[38]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[39]  J. Ihle.  STATs: Signal Transducers and Activators of Transcription , 1996, Cell.

[40]  E. Lakatta,et al.  PDGF receptor-to-nucleus signaling of p91 (STAT1 alpha) transcription factor in rat smooth muscle cells. , 1996, Experimental cell research.

[41]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[42]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[43]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[44]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[45]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[46]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[47]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[48]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[49]  Xin-Yuan Fu,et al.  Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter , 1993, Cell.

[50]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[51]  J. Darnell,et al.  Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. , 1992, Science.

[52]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[53]  R. Eddy,et al.  Identification of a new endothelial cell growth factor receptor tyrosine kinase. , 1991, Oncogene.

[54]  D. Gospodarowicz,et al.  Characterization of the receptors for vascular endothelial growth factor. , 1990, The Journal of biological chemistry.

[55]  W. Wierda.  Molecular Biology of Chronic Lymphocytic Leukemia , 2004 .

[56]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[57]  T. Kipps.  Chronic lymphocytic leukemia , 1998, Current opinion in hematology.